<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04965831</url>
  </required_header>
  <id_info>
    <org_study_id>AST-PMR2003</org_study_id>
    <nct_id>NCT04965831</nct_id>
  </id_info>
  <brief_title>Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT)</brief_title>
  <official_title>Furmonertinib Mesylate as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable, EGFR Sensitizing Mutation Positive Lung Adenocarcinoma Patients: A Phase II, Single-arm, Open-label Clinical Study (FRONT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allist Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II study aimed to assess the efficacy and safety of furmonertinib, a third&#xD;
      generation EGFR TKI, as perioperation therapy in stage IIIA-IIIB (N1-N2) resectable NSCLC&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Please refer to detailed description in the following context.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Approximately 8 weeks following the first dose of study drug</time_frame>
    <description>Proportion of patients whose tumors were assessed as complete response(CR) or partial response(PR) according to RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Approximately 8 weeks following the first dose of study drug</time_frame>
    <description>Proportion of patients whose tumors were assessed as CR, PR or stable disease (SD) according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Approximately 3 years following the first dose of study drug</time_frame>
    <description>The time from the first does of the study drugs to the progression of the disease or death for any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival (DFS)</measure>
    <time_frame>Approximately 3 years following the first dose of study drug</time_frame>
    <description>The time from the end of surgery to the progression of the disease or death for any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>From the start of study drug to 28 days after the last dose of study drug</time_frame>
    <description>The number of patients with adverse events and the severity according to CTCAE v5.0</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Circulating tumor DNA clearance rate</measure>
    <time_frame>Approximately 8 weeks following the first dose of study drug</time_frame>
    <description>The proportion of patients with circulating tumor DNA clearance after neoadjuvant therapy</description>
  </other_outcome>
  <other_outcome>
    <measure>Minimal residual disease rate</measure>
    <time_frame>Approximately 12 weeks following the first dose of study drug</time_frame>
    <description>The proportion of patients with minimal residual disease defined as detectable ctDNA with a variant allele fraction of at least 0.1% in plasma after surgery</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Lung Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Furmonertinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Furmonertinib as perioperation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furmonertinib</intervention_name>
    <description>Furmonertinib 80mg/d as neoadjuvant therapy for 8 weeks before surgery, then as adjuvant therapy for 3 years after surgery.</description>
    <arm_group_label>Furmonertinib</arm_group_label>
    <other_name>AST2818</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The written informed consent of the patients has been obtained before any examination,&#xD;
             sampling and analysis related to the study.&#xD;
&#xD;
          -  Primary lung adenocarcinoma diagnosed histologically/cytologically.&#xD;
&#xD;
          -  Stages IIIA-IIIB (N1-N2) according to the AJCC 8th edition lung cancer stage and plan&#xD;
             to receive radical excision judged by investigators.&#xD;
&#xD;
          -  EGFR mutation positive (19Del or L858R, with or without T790M)&#xD;
&#xD;
          -  The presence of at least one measurable lesion and suitable for accurate repeated&#xD;
             measurements.&#xD;
&#xD;
          -  ECOG performance status 0-1.&#xD;
&#xD;
          -  For premenopausal women with fertility, the result of serum or urine pregnancy test&#xD;
             should be negative within 7 days before the first dose.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Squamous cell carcinoma, and tumors with neuroendocrine components such as large cell&#xD;
             carcinoma, or small cell carcinoma.&#xD;
&#xD;
          -  Patients with EGFR exon 20 insertion mutation.&#xD;
&#xD;
          -  Exposure to other antitumor therapies prior to enrolment.&#xD;
&#xD;
          -  Major surgery was performed in the four weeks prior to the first dosing of the study&#xD;
             drug.&#xD;
&#xD;
          -  Pregnant or lactating female patients.&#xD;
&#xD;
          -  Use of CYP3A4 strong depressant within 7 days or CYP3A4 strong inducer within 21 days&#xD;
             prior to initial administration.&#xD;
&#xD;
          -  Have a history of or present complications with other malignancies.&#xD;
&#xD;
          -  Patients with severe or uncontrolled systemic disease requiring treatment were not&#xD;
             considered suitable for the study.&#xD;
&#xD;
          -  ECG QT interval prolongation or associated risk.&#xD;
&#xD;
          -  A history of interstitial pneumonia or related risk.&#xD;
&#xD;
          -  Inadequate bone marrow or organ reserve.&#xD;
&#xD;
          -  Other circumstances that are not suitable for participation in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Changli Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tianjin Medical University Cancer Institute and Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Changli Wang, MD</last_name>
    <phone>+86 022-23340123</phone>
    <email>aswindcc@126.com</email>
  </overall_contact>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 27, 2021</study_first_submitted>
  <study_first_submitted_qc>July 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2021</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Adenocarcinoma of Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aflutinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The IPD sharing plan is not to be shared according to the policy.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

